|1.||Lee, Chul-Hoon: 3 articles (02/2010 - 06/2005)|
|2.||Cho, Youl-Hee: 2 articles (05/2006 - 06/2005)|
|3.||Kim, Min Kyoung: 2 articles (05/2006 - 06/2005)|
|4.||Rayala, Ramanjaneyulu: 1 article (09/2014)|
|5.||Robins, Morris J: 1 article (09/2014)|
|6.||Yao, Sylvia: 1 article (09/2014)|
|7.||Theard, Patricia: 1 article (09/2014)|
|8.||Wnuk, Stanislaw F: 1 article (09/2014)|
|9.||Balzarini, Jan: 1 article (09/2014)|
|10.||Ortiz, Heysell: 1 article (09/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
|3.||AIDS-Related Complex (ARC)
01/01/2009 - "Furthermore, functional overlap between ARC and sangivamycin suggests that development of ARC may benefit from a retrospective of previous sangivamycin clinical trials. "
01/01/2009 - "ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC."
01/01/2009 - "Results demonstrated that sangivamycin, an extensively characterized pro-apoptotic nucleoside isolated from Streptomyces, had identical activity to ARC in terms of 1) cytotoxicity assays, 2) ability to induce a G2/M block, 3) inhibitory effects on RNA/DNA/protein synthesis, 4) transcriptomic response to treatment, 5) inhibition of protein kinase C, 6) inhibition of positive transcription elongation factor b (P-TEFb), 7) inhibition of VEGF secretion, and 8) activity within hollow fiber assays. "
02/07/2014 - "Our data thus indicate that sangivamycin may find clinical utility as a novel anti-cancer agent targeting PEL. "
11/01/2007 - "After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. "
05/18/2007 - "Sangivamycin has shown a potent antiproliferative activity against a variety of human cancers. "
09/01/2014 - "Type-specific inhibition of cancer cell proliferation was observed at micromolar concentrations with the 4-N-(4-nitrobenzyl) derivatives of sangivamycin and toyocamycin, and also with 4-N-benzyltubercidin. "
11/01/2007 - "Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin."
11/01/1981 - "Cytokinetic and biochemical effects of sangivamycin in human colon carcinoma cells in culture."
05/18/2007 - "Here we demonstrate that sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death. "
11/01/1983 - "In vitro translational activity of messenger RNA following treatment of human colon carcinoma cells with sangivamycin."
05/18/2007 - "The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation."
03/01/1985 - "Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells."
|4.||RNA (Ribonucleic Acid)
|6.||Protein Kinase C
|7.||DNA (Deoxyribonucleic Acid)
|10.||Caspase 3 (Caspase-3)